ALK and non-small cell lung carcinoma: MTT-based viability assays revealed notably higher half-maximal inhibitory concentration (IC50) values to crizotinib in H2228 cells than in H3122 cells, confirming that NSCLC cells with the variant 3a/b have an inferior response to ALK–TKIs and more aggressive behavior that those with variant 1 (Table S1; Figure 1C) [58,59,60,61].